{
  "document_id": "NeuroboPharmaceuticalsInc_20190903_S-4_EX-10.36_11802165_EX-10.36_Manufacturing Agreement_ Supply Agreement",
  "file_path": "data/CUAD_v1/full_contract_pdf/Part_I/Manufacturing/NeuroboPharmaceuticalsInc_20190903_S-4_EX-10.36_11802165_EX-10.36_Manufacturing Agreement_ Supply Agreement.pdf",
  "text_length": 20019,
  "chunk_count": 28,
  "vector_store_path": "output/vector_stores/NeuroboPharmaceuticalsInc_20190903_S-4_EX-10.36_11802165_EX-10.36_Manufacturing Agreement_ Supply Agreement",
  "summary": "(b)  if the breach cannot reasonably be cured within the [***]-day period, the breaching Party has not started to remedy the breach\nwithin the [***]-day period and diligently endeavored to cure the breach within a reasonable time thereafter.\n5.4  Either Party may terminate this Agreement immediately upon notice to the other Party in the event that (a) the other Party is the subject\nof a petition for bankruptcy, reorganization, or arrangement, whether voluntary or involuntary, and the same is not dismissed within thirty (30) days\nthereof, (b) a receiver or trustee is appointed for all or a substantial portion of the assets of the other Party, or (c) the other Party makes an\nassignment for the benefit of its creditors.\n5.6  The termination or expiration of this Agreement, in whole or in part, shall be without prejudice to the right of either Dong-A and NeuroBo\n\nIN WITNESS WHEREOF,  the Parties hereto have duly executed this Agreement as of the Effective Date.\nDONG-A ST CO., LTD .\nBy: /s/ Daesik Eom\nDaesik Eom, Chairman and CEO\nNEUROBO PHARMACEUTICALS, INC.\nBy: /s/ John L. Brooks, III\nJohn L. Brooks III, President & CEO\n7\nExhibit A\nProduct Specifications\nTestAnalytical\nMethod Specification Requirements\n[***] [***] [***]\n[***][***] [***]\n[***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\nSchedule 1- 1\nSource: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019\n\nExhibit B\nProduct Test Methods\n[***]\nSchedule 1- 2\nSource: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019\n\nNOW, THEREFORE , in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable\nconsideration, the receipt and sufficiency of which are hereby acknowledged, Dong-A and NeuroBo mutually agree as follows:\n1.  DEFINITIONS\nUnless otherwise defined in this Agreement, the capitalized terms utilized herein shall have\n1\nSource: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019\n\nAgreement. Notice of change of address shall be given in the same manner as other communications.\n8.  INCORPORATION BY REFERENCE\nArticles  or Sections 8.2 (Limitation of Liability), 9 (Indemnification), 12.2 (Force Majeure), 12.3 (Assignment), 12.4 (Severability), 12.6 (Remedies),\n12.8 (Submission to Jurisdiction/Waiver of Jury Trial), 12.9 (Independent Contractor/No Agency), 12.10 (Entire Agreement) of the License\nAgreement shall be deemed to be incorporated herein by reference as it is set forth in this Agreement\n<Signature page follows .>\n6\nSource: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019",
  "parties": "Agreement. Notice of change of address shall be given in the same manner as other communications.\n8.  INCORPORATION BY REFERENCE\nArticles  or Sections 8.2 (Limitation of Liability), 9 (Indemnification), 12.2 (Force Majeure), 12.3 (Assignment), 12.4 (Severability), 12.6 (Remedies),\n12.8 (Submission to Jurisdiction/Waiver of Jury Trial), 12.9 (Independent Contractor/No Agency), 12.10 (Entire Agreement) of the License\nAgreement shall be deemed to be incorporated herein by reference as it is set forth in this Agreement\n<Signature page follows .>\n6\nSource: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019\n\nProducts and/or their matching placebo, (ii) the specifications of the Licensed Products and/or their matching placebo, including the specifics of\npackaging, (iii) the expected delivery date for the API, (iv) the requested delivery date for the Licensed Products and/or their matching placebo, (v)\nthe shipment terms for the Licensed Products and/or their matching placebo and (vi) the supply price for the Licensed Products and/or their\nmatching placebo. Upon receipt of the order from NeuroBo, Dong-A shall promptly acknowledge the receipt of such order. No order shall be\nbinding upon the Parties until agreed in writing by Dong-A and NeuroBo\u037e provided, however,  that such agreement shall not be unreasonably\nwithheld or delayed. Upon such agreement, the order shall be deemed to be the \u201c Firm Order \u201d which shall be binding and may only be revised by\nagreement of the Parties in writing. Dong-A shall deliver the Licensed Products and/or their matching placebo to NeuroBo in accordance with the\n\nLicensed Products and/or their matching placebo does not meet the Product Specifications, (i) Dong-A shall arrange for the return from NeuroBo of\nthe Licensed Products and/or their matching placebo at Dong-A\u2019s expense, and (ii) without waiting for the return, Dong-A shall promptly replace\nthe Licensed Products and/or their matching placebo at no additional cost to NeuroBo.\n4.  TERMS AND CONDITIONS OF SALE\n4.1  The terms and conditions of sale and purchase of the Licensed Products and/or their matching placebo between Dong-A and NeuroBo\nshall be set forth in each Firm Order.\n4.2  The supply prices for the Licensed Products and their matching placebo shall be specified in Schedule 4.2.\n4.3  Upon agreement by the Parties of the Firm Order, Dong-A shall issue to NeuroBo an invoice in Korean Won for each shipment of the\nLicensed Products and/or their matching placebo based on the Firm Order. Unless otherwise agreed in writing by Dong-A, NeuroBo shall pay the\n\nnor shall bring any claims or actions against Dong-A for any such deficiencies and/or costs or damages NeuroBo may incur resulting therefrom.\nUpon request of Dong-A, the Parties may discuss in good faith a plan for NeuroBo to assist in correcting such deficiencies and the terms and\nconditions for implementing the corrective actions under such plan.\n2.6  The Parties acknowledge and agree that prior to commercialization of the Licensed Products by NeuroBo, its Affiliates and/or\nsublicensees, the Parties shall, in good faith, negotiate the terms and conditions for, including, without limitation, the supply price, and enter into a\ndefinitive non-exclusive supply agreement pursuant to which Dong-A shall supply to NeuroBo the Licensed Products for the commercialization by\nNeuroBo, its Affiliates and/or sublicensees of the Licensed Products in the Field in the Territory pursuant to the License Agreement.",
  "key_terms": "(b)  if the breach cannot reasonably be cured within the [***]-day period, the breaching Party has not started to remedy the breach\nwithin the [***]-day period and diligently endeavored to cure the breach within a reasonable time thereafter.\n5.4  Either Party may terminate this Agreement immediately upon notice to the other Party in the event that (a) the other Party is the subject\nof a petition for bankruptcy, reorganization, or arrangement, whether voluntary or involuntary, and the same is not dismissed within thirty (30) days\nthereof, (b) a receiver or trustee is appointed for all or a substantial portion of the assets of the other Party, or (c) the other Party makes an\nassignment for the benefit of its creditors.\n5.6  The termination or expiration of this Agreement, in whole or in part, shall be without prejudice to the right of either Dong-A and NeuroBo\n\napplicable laws, including any applicable anti-corruption or anti-bribery laws or regulation, of any governmental authority with jurisdiction over the\nactivities performed by NeuroBo or its Affiliates or sublicensees in furtherance of such obligations.\n5.  TERM AND TERMINATION\n5.1  This Agreement shall commence on the Effective Date and, unless earlier terminated, shall continue in full force and effect for a period of\n[***] years thereafter.\n5.2  This Agreement shall automatically terminate in case the License Agreement is terminated for any reason specified therein.\n5.3  A Party may terminate this Agreement by notice to the other Party if the other Party is in material breach of any provision of this\nAgreement, and\n(a)  the breaching Party has not cured the breach within [***] days after receiving notice from the terminating Party\u037e or\n(b)  if the breach cannot reasonably be cured within the [***]-day period, the breaching Party has not started to remedy the breach\n\n6.  GOVERNING LAW\nThe laws of the State of New York (without giving effect to its conflicts of law principles) govern all matters arising out of or relating to\nthis Agreement and all of the transactions it contemplates, including without limitation, its validity, interpretation, construction, performance, and\nenforcement.\n7.  NOTICES\nAll notices, consents, and approvals under this Agreement must be delivered in writing by courier, electronic facsimile (fax), or certified or\nregistered mail, (postage prepaid and return receipt requested) to the other Party\u037e and shall be effective upon receipt or three (3) business days\nafter being deposited in the mail, whichever occurs sooner. Notices to the Parties shall be sent to the addresses set forth at the beginning of this\nAgreement. Notice of change of address shall be given in the same manner as other communications.\n8.  INCORPORATION BY REFERENCE\n\nProducts and/or their matching placebo, (ii) the specifications of the Licensed Products and/or their matching placebo, including the specifics of\npackaging, (iii) the expected delivery date for the API, (iv) the requested delivery date for the Licensed Products and/or their matching placebo, (v)\nthe shipment terms for the Licensed Products and/or their matching placebo and (vi) the supply price for the Licensed Products and/or their\nmatching placebo. Upon receipt of the order from NeuroBo, Dong-A shall promptly acknowledge the receipt of such order. No order shall be\nbinding upon the Parties until agreed in writing by Dong-A and NeuroBo\u037e provided, however,  that such agreement shall not be unreasonably\nwithheld or delayed. Upon such agreement, the order shall be deemed to be the \u201c Firm Order \u201d which shall be binding and may only be revised by\nagreement of the Parties in writing. Dong-A shall deliver the Licensed Products and/or their matching placebo to NeuroBo in accordance with the"
}